אולנזאפין דקסל 10 מ"ג

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

OLANZAPINE 10 MG

Disponible depuis:

DEXCEL PHARMA TECHNOLOGIES LTD

Code ATC:

N05AH03

forme pharmaceutique:

TABLETS

Mode d'administration:

PER OS

Fabriqué par:

DEXCEL LTD

Groupe thérapeutique:

OLANZAPINE

indications thérapeutiques:

Acute and maintenance treatment of schizophrenia. Olanzapine is indicated for the management of the manifestations of psychotic disorders. Olanzapine is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder : the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.

Date de l'autorisation:

2012-05-01